Genmab after Merus acquisition

Genmab strengthens position among global immunotherapy leaders with Merus acquisition

From a patent perspective, the acquisition represents a highly strategic move. Genmab now advances to position 25 among the leading immunotherapy companies, measured by the number of world-class patents. This transaction further strengthens Genmab’s already robust market position. Roche and Bristol Myers Squibb remain industry leaders.

When focusing on specialized immunotherapy companies—those with more than half of their patents in this field—the acquisition elevates Genmab into the global top 5, ranking just behind Incyte and BioNTech. For BioNTech, the planned acquisition of CureVac has also been factored into the calculations. Both transactions underscore the accelerating activity among specialized companies racing for leadership in immunotherapy.

Merus, one of the world’s most innovative immuno-oncology companies, has been part of the EconSight GameChanger Portfolio for the past two years. The GameChanger Portfolio highlights the 25 most dynamic companies in global patent development. The acquisition of Merus will also prompt an update to the EconSight GameChanger Portfolio, with Genmab replacing Merus directly in the index.